UPDATE: Please see this post for an important update to this issue.

The Washington Department of Health (“DOH”) held a public meeting on October 9 where they discussed Governor Jay Inslee’s recent executive order requesting that the DOH adopt emergency rules banning flavored vapor products, including flavored cannabis vapor products, and voted to adopt an emergency rule banning the products. The new rules use a defined term for “characteristic flavor,” which is used to distinguish permissible vapor products from impermissible ones. These rules will significantly affect the cannabis industry, but it is important to note that the rule does not amount to an outright ban of all cannabis vapor products.

In the Wake of an Outbreak

This flurry of government activity comes in the wake of an outbreak of illnesses and deaths across the United States related to vaporizing, and numerous other states have issued bans of their own. DOH’s stated reason for adopting the emergency rules is concern for public health and protecting youth:

The State Board of Health’s Health Impact Review of HB 1932 found strong evidence that prohibiting the sale of flavored vapor products will likely decrease initiation and use of vapor products among adolescents and young adults. Reducing the initiation and use of vapor products by youth and young adults will reduce the exposure of our most vulnerable population to the current outbreak of severe lung disease associated with the use of vapor products.

The cause of the outbreak has yet to be determined. While reducing youth use of vapor products is a legitimate goal, the ban is questionable if the recent illnesses are in fact found to be a result of substances other than flavoring, or the ban does not reduce overall consumption rates. The DOH emergency rules cite the 2018 Washington State Healthy Youth Survey which showed an increase in teen use of tobacco vapor products. However, that same survey showed that use of cannabis overall did not increase post-legalization, and in some instances actually decreased.

“Characterizing Flavor” Defined

The DOH emergency rules defines flavored vapor product as “any vapor product that imparts a characterizing flavor,” which in turn is defined as:

‘Characterizing flavor’ means a distinguishable taste or aroma, or both, other than the taste or aroma of tobacco or marijuana or a taste or aroma derived from compounds or derivatives such as terpenes or terpenoids derived directly and solely from marijuana, as defined in RCW 69.50.101(y), or hemp plants that have been grown and tested as required by state law, imparted by a vapor product. Characterizing flavors include, but are not limited to, tastes or aromas relating to any fruit, chocolate, vanilla, honey, candy, cocoa, dessert, alcoholic beverage, menthol, mint, wintergreen, herb, or spice. A vapor product does not have a characterizing flavor solely because of the use of additives or flavorings or the provision of ingredient information. It is the presence of a distinguishable taste or aroma, or both, that constitutes a characterizing flavor.

It is important to recognize that “characterizing flavor” does not include the natural taste or aroma of cannabis or hemp, or of terpenes or terpenoids derived from cannabis hemp. Thus, cannabis vapor products containing taste or aroma profiles derived from cannabis or hemp should be permissible. It is noteworthy that this ban only pertains to those compounds with a “distinguishable taste or aroma,” so compounds that do not have such qualities likely could still be added after this rule.

Terpenes: Derived from Where? The Rule’s Ambiguity

Though it is not obvious, cannabis producers regularly add terpenes to their products to enhance the natural flavors and aromas of the plant. Some of these terpenes are derived from cannabis, some from hemp, and some from other sources.

For the uninitiated, terpenes are organic compounds produced in many different plants (even some insects) that often emit a strong odor. Limonene, for example, is a terpene that is naturally produced by cannabis and is found in popular strains for its citrus flavor (see: Lemon Haze). But it’s also naturally produced by lemons and oranges, and you can often find it in your lemon-scented essential oils or dish soap.

Some may interpret the rule’s definition carving out a taste or aroma derived from marijuana or hemp to mean that tastes or aromas from other sources and added to a vape product result in a prohibited flavored vape product. However, it can—and arguably should–also be interpreted that key to the definition of “characterizing flavor” is that it is a distinguishable taste or aroma other than tobacco or marijuana, implying that non-marijuana/hemp derived compounds that provide the taste or aroma of marijuana could be allowable. Further, it could be argued that the carve-out for tastes and aromas from marijuana or hemp permits tastes and aromas other than tobacco or cannabis.

The last two sentences in the definition of “characterizing flavor” support the interpretation that vape products may include non-marijuana and hemp additives. Those sentences provide that a vapor product does not have a characterizing flavor “solely because of the use of additives or flavorings or the provision of ingredient information. It is the presence of a distinguishable taste or aroma, or both, that constitutes a characterizing flavor.” This supports a position that additives or flavorings may be added provided they do not otherwise result in a characterizing flavor.

Some cannabis stores have already stopped selling any vapor products that include any non-marijuana/hemp-derived compounds. We anticipate further guidance on these issues. The key takeaways from the current rules are as follows:

  • Marijuana/hemp-derived compounds are allowable, regardless of what taste or aroma they result in;
  • Non-marijuana/hemp-derived compounds that provide the taste or aroma of cannabis could be allowable, though the rule isn’t explicitly clear; and
  • Non-marijuana/hemp-derived compounds that result in a non-cannabis taste or aroma (such as a fruit, chocolate, honey, etc.) are likely not allowable.

The WSLCB Responds

Hours after the DOH vote on October 9, the Washington State Liquor and Cannabis Board (“WSLCB”) emailed stakeholders notifying that, effective midnight, flavored vapor products could no longer be sold to retail stores by processors or to the general public. The WSLCB also (1) required retail stores to prominently post this warning sign in their stores, (2) reminded licensees of packaging and labeling rules, (3) required licensees to disclose to the WSLCB all compounds used in the production and processing of vapor products, and (4) required licensee to cooperate with the ongoing epidemiological investigation.

Cannabis producers and processors will be grappling with these new rules, and can expect more follow-up regulations from the WSLCB. It remains unclear how these rules will be enforced, and what the penalties for non-compliance will be. Regardless, companies would be well advised to be aware of the new rules.

On September 17, Senate Majority Leader Mitch McConnell proposed language that directs the U.S. Food and Drug Administration (“FDA”) to issue policies on regulating and enforcing regulations on the use hemp-derived cannabidiol (“CBD”) in products. This language would be inserted into a congressional spending report and would direct the FDA to provide a report to congress within 90 days, stating the FDA’s “progress” towards analyzing data to determine its policy of enforcement discretion. Secondly, the language would direct the FDA to issue a policy on that enforcement discretion concerning “certain products containing CBD meeting the definition of hemp[.]” Though this has been reported as clearing a path for CBD products, that is not necessarily the case.

The FDA’s Current Position on CBD

When the Farm Bill passed late last year, then-FDA Commissioner Scott Gottlieb issued a press release stating that it is unlawful to sell food or dietary supplements containing hemp-derived CBD, mainly because it is an active ingredient in the FDA-approved drug Epidiolex. This position was reiterated earlier this year and remains the agency’s current position. The FDA did have a public hearing on May 31, 2019, to discuss these products, and there have been rumors of the FDA may loosen this position in the future. But until that occurs, companies selling these products do so at risk of enforcement action from the federal government (and from local and state government), particularly if they do so while making medical claims about the products.

The Proposed Language

The proposed language does not specify which products the FDA will issue a policy on; it merely uses the term “products.” Presumably the FDA will have to issue a policy for both food and dietary supplements. Currently, the FDA is not scrutinizing cosmetics that contain hemp-derived CBD. What’s most important to note in this language is that it directs the FDA to determine a “policy of enforcement discretion,” which is quite vague. The FDA could simply implement its current policy of prohibiting food and dietary supplements containing hemp-derived CBD.

The language also states,

FDA is encouraged to consider existing and ongoing medical research related to CBD that is being undertaken pursuant to an Investigation New Drug (IND) application in the development of a regulatory pathway for CBD in products under the jurisdiction of FDA and to ensure that any future regulatory activity does not discourage the development of new drugs.

Existing and ongoing medical research is generally showing CBD to be potentially beneficial for a number of different diseases. But that doesn’t mean that it can, or should, be used in food or dietary supplement. The language just doesn’t seem narrow enough to direct the FDA one way or the other.

But this proposed language should be taken in the context of other congressional pressure on the FDA. Last week, two representatives (from both political parties) circulated a letter to the House urging their colleagues to demand the FDA establish regulations that would allow the use of hemp-derived CBD in food and dietary supplements. The letter points out that though CBD is currently classified as a drug (Epidiolex), it has the authority to classify lower doses of CBD in food and dietary supplements as allowable.

This is on top of a budget amendment approved in June setting aside funds for the FDA to set a “safe level for conventional foods and dietary supplements containing cannabidiol (CBD).” While this amendment still needs to be approved by the whole House and by the Senate, the FDA may take these signs and move to regulate CBD products in a less strict manner than its current position.

Potential for Preemption?

When the FDA does issue final regulations on food and dietary supplements containing hemp-derived CBD, questions will remain as to whether those rules will trump state laws already passed on the subject. The Supremacy Clause of the U.S. Constitution states that when federal and state laws conflict, or where the federal government has clearly laid out a regulatory field for itself, conflicting state law will be invalidated. This will likely be an issue for CBD laws.

Take California for example, where AB 228 is currently winding its way through the legislature, and states that food containing CBD regulated by state law will not be considered adulterated. Many other states have similar laws already, including Colorado, Maine, New Mexico, and Wisconsin. Will these laws be preempted by FDA policy? They likely will, which will then set up yet another conflict between federal and state law and leave open the question of whether the states will have an appetite to openly defy the federal government (like states have done by legalizing cannabis), and whether the federal government will in turn have an appetite to enforce federal law.

Michigan’s Marijuana Regulatory Agency (MRA) issued its emergency administrative rules earlier this month, providing a framework for the state’s adult-use cannabis industry and detailing the license application process. The MRA stated in their July 3 press release that they plan to start accepting business applications on November 1.

Perhaps the most important rule that entrepreneurs should know: the MRA will only accept applications from businesses already licensed under Michigan’s medical cannabis laws for the first two years. This limitation was included in the ballot initiative that voters approved in November of 2018. So if one isn’t already licensed by the MRA, they may want to begin the application to become a licensed medical facility first. One can buy a preexisting licensed medical facility as well, though they will still have to obtain MRA approval for the purchase. The medical rules initially required that applicants be residents of Michigan, but this has since expired and applicants can now be out-of-state.

The MRA will accept applications for 12 different types of licenses under the adult-use rules, including retailers, secure transporters, safety compliance facilities, microbusinesses and growers. Grower licenses divided into Class A (up to 100 plants), Class B (up to 500 plants) and Class C (up to 2,000 plants).

The Application Process

The non-refundable application fee is $6,000. If a business isn’t already a licensee under the medical cannabis laws, they would have to complete that application process first, which would involve a separate $6,000 fee in addition to the adult-use application fee. The two are separate processes, but the new adult-use rules largely mirror the medical rules. Applicants should expect the application and approval processes to be very similar. Licensees will also have to pay annual licensure fees that are substantial compared to other states. The annual fees are separated into three tiers depending on the volume of a license’s sales compared to the market, so better performing businesses will pay higher fees than others will. Annual fees for retailers will range between $20,000 and $30,000. Annual feels for Class C growers will range between $30,000 and $50,000.

The application process is divided into two stages: pre-qualification and the license application. Pre-qualification includes criminal and financial background checks as well as an examination on the applicant’s feasibility. In order to proceed to the second stage, the applicant will need a compliant location and to provide the local ordinance of the municipality showing that cannabis businesses are allowed there. So applicants can begin the application process before they have found a location, but they will need a compliant location in order to obtain approval. If an applicant already has a location, they can begin both stages simultaneously, or nearly so.

Social Equity

One interesting facet of the rules is the requirement for businesses to detail plans to “promote and encourage participation in the marihuana industry by people from communities that have been disproportionately impacted by marihuana prohibition and enforcement and to positively impact those communities.”

The rules don’t go into further detail as to what a social-equity plan would look like. Social justice issues have often been included as reasons for legalizing cannabis, though actual measures have varied to encourage participation by “communities that have been disproportionately impacted by marihuana prohibition,” (which is essentially a careful approach to saying communities of color). Washington state has done very little, while cities like Oakland and Los Angeles have dedicated programs, though whether such programs have been a success remains unclear.

One roadblock that has already been removed for these communities is that the capitalization requirement for new applications have been removed. Medical cannabis applicants had to provide they had adequate capitalization (meaning, funding) to open their businesses, leaving many without access to capital out of the regulated industry. The new adult-use rules do away with this.

Resources

The MRA has provided a number of resources for license applicants. Businesses looking to apply for a Michigan medical cannabis license can apply here, though one may want to consult an attorney experienced in the space. The MRA has also provided an application instruction booklet.

Gabi Sanchez, Co-Chair of our Senior Living & Long Term Care Team, was quoted in a recent Senior Living Executive magazine article titled “Cannabis, Choice, and Your Community: Updates on Practices and Problems.” The article, authored by Cynthia Helzel, discusses the increase of older adults turning to cannabis products as well as the impacts this trend has on senior living and long term care communities.

‘It’s important for executives to pay attention to this issue,’ said Gabriela Sanchez, shareholder and co-chair of the senior living and long-term care team at the law firm Lane Powell. ‘Based on the statistics and the changing perceptions of marijuana, people are going to demand use of marijuana in their communities, and in fact they already are.’

In the article, Gabi offered guidance on smoking bans in these communities:

‘We actually recommend that you don’t allow smoking of any kind of marijuana, whether it’s hemp CBD or marijuana-based CBD,’ Sanchez said. ‘Everything should be non-smoking because if not, you bring into play all sorts of other laws.’

She also provided this tip on setting community cannabis policies:

The more transparent you are with your residents about what you allow and do not allow, the easier it’s going to be for you to enforce your policies and your rules and to limit your liability.

Read the full article.

SB 5318 was signed into law in Washington on May 13, and requires the Washington State Liquor and Cannabis Board (WSLCB) to overhaul its practices when enforcing cannabis regulations. But even before the bill was signed, a look through the WSLCB’s Adjudicative Proceedings Log indicates that the WSLCB had already begun making some changes in how it handled certain license-cancelling administrative violation notices (AVN). In particular, the WSLCB in 2019 has been more willing to agree to levy large financial penalties against cannabis businesses rather than cancel their licenses outright.

Cannabis businesses in Washington are quite familiar with the dreaded “True Party of Interest” AVN, which can be issued for a variety of circumstances including hidden ownership, hidden control, out-of-state ownership, undisclosed financiers, and other issues relating to the overall control or ownership of the business.

A News Article and a Spike in License Cancellations

Two years ago, Bob Young of The Seattle Times published an article criticizing the WSLCB for not cancelling licenses for hiding owners (or financiers) as is stated in WAC 314-55-530 as the appropriate penalty. Young stated that of the 36 hidden-ownership violations that had been issued since sales began in 2014, only three had led to canceled licenses. Young highlighted the case of Vela, a retail store in the SoDo district of Seattle, as a classic example of hidden ownership in which the WSLCB issued a $50,000 fine rather than canceling the license.

Since that article was published, there have been 28 final decisions from the WSLCB concerning True Party of Interest violations. Of those 28, 15 licenses were cancelled. Two others were given the opportunity to sell the license or face cancellation. Not a single fine was issued in lieu of license cancellation. Note that this only counts cases that were appealed, and not licenses that were cancelled without an appeal.

One can speculate as to what caused this spike in license cancellations — 15 (or 17 if you prefer) cancellations over two years compared to three cancellations over the three preceding years, and no large fines. It may have been related to the Times article, or it may have been related to the election of Donald Trump and his naming of anti-cannabis Jeff Sessions as his Attorney General. Or WSLCB may not have changed anything and the difference was simply by chance. Whatever the cause, the spike was clear.

A Letter From Legislators and SB 5318

Many in the industry cried foul, claiming that licenses were being cancelled as a result of inadequate or unfair investigations, and that businesses were being shut down for minor violations or mistakes. The issue came to a boil when in January 2019 a bipartisan group of 10 state legislators wrote a letter calling on Governor Jay Inslee to rescind the nomination of WSLCB board member Russ Hauge, complaining of a “toxic culture” at the WSLCB and taking issue with the severe penalties being levied against cannabis businesses.

At the same time, SB 5318 was introduced, which requires the WSLCB (a) consider de minimis violations (too small to merit consideration), (b) waive violations that are quickly rectified, (c) establish a compliance program for businesses, and (d) cease license cancelling on a first offense for many types of violations unless those violations concerned threats to public safety.

Recent Penalties: Large Fines Return

Even before SB 5318 was voted on, let alone signed, the WSLCB appeared to have finally gotten the message and changed its tune. Thus far, in 2019 the WSLCB has issued eight final decisions regarding True Party of Interest Violations. Of those eight, four have canceled licenses while the other four instead have levied fines of $50,000 or $75,000. This is remarkable when compared to 2018 and the second half of 2017 (following the Times article), in which not a single large fine was levied for a True Party of Interest Violation and 11 licenses were cancelled (and an additional two required to be sold or face cancellation).

The WSLCB has yet to issue its new administrative rules following the directive of SB 5318, but the above indicates just how wide a discretion the WSLCB is afforded in how it issues penalties that decide the life or death of a business. It also seems eminently clear that, regardless of law, the WSLCB is influenced by politics.

SB 5318 requires the WSLCB to reform, and it will issue new rules later this year. Washington cannabis businesses may enjoy a softer regulatory agency that should allow them space to get into compliance without penalty, and afford them alternatives to cancelling their license. Still, agency culture does not change easily, and businesses should be cautious and be aware that WSLCB continues to have wide discretion in what penalties it issues and how it investigates businesses. But businesses facing a True Party of Interest AVN may again entertain taking a large fine rather than losing their business, and they should review the new rules when they are released.

On May 28, the U.S. Department of Agriculture (USDA) issued a legal opinion that discusses the hemp-related provisions of the 2018 Farm Bill. Two of the issues addressed in the opinion are noteworthy:

Interstate Transportation

The USDA opines that states and Indian tribes may not prohibit the interstate transportation or shipment of hemp lawfully produced under the 2014 Farm Bill. This conclusion is likely to have a meaningful impact on hemp produced during the current growing season under 2014 Farm Bill programs and pending legal matters involving interstate shipments of hemp. It will be interesting to see what, if any, weight the Ninth Circuit Court of Appeals gives to the USDA position in the Big Sky Scientific case we previously covered here. Further, it will be interesting to see how states adjust to the USDA position.

Hemp and the CSA

The USDA memo opines, “hemp has been removed from schedule I of the Controlled Substances Act and is no longer a controlled substance.” The memo notes that removal provisions in the 2018 Farm Bill were self-executing and do not require further action by the USDA. Taken at face value, this position appears benign. We have previously covered the Controlled Substance Act’s (CSA) definition of marihuana here. Please note that we continue to use the spelling “marihuana” given its use as a defined term in the CSA.

Prior to the 2014 and 2018 Farm Bills, certain parts of the cannabis plant were not controlled substances (e.g., mature stalks and sterilized seeds) because of a specific carve out within the definition of marihuana. Following the 2018 Farm Bill, the term marihuana does not include “hemp” as defined in section 297A of the Agricultural Marketing Act of 1946. That section of the Agricultural Marketing Act defines hemp as cannabis having a THC concentration of less than 0.3% on a dry weight basis.

Marihuana and THC are separately included as Schedule I controlled substances within the CSA. THC that is not marihuana is still a Schedule I substance. The 2018 Farm Bill addressed the THC issue by excluding THC “in hemp.” This raises the question and potential conflict that any THC derived from hemp is not a controlled substance whereas THC derived from cannabis not meeting the definition of hemp is a controlled substance. Potential conflicts are likely to arise due to hemp derivatives. If THC in hemp is not a controlled substance, then one might argue that THC derived from hemp is similarly not a controlled substance.

Many of us might be familiar with the saying that hemp does not get you high, or that the quantity of hemp that you would need to consume to get you “high” is too much for any one person. However, if we can legally concentrate or extract THC in hemp without the resulting product becoming a controlled substance, then enforcement problems arise. THC distillate from hemp? This is arguably not a controlled substance. THC from cannabis that is not hemp? Still a controlled substance. This distinction is likely to make cannabis extract and concentrate enforcement efforts futile.

The definition of hemp depends on the plant’s concentration of THC. Our unscientific understanding of THC production within cannabis is that THC production generally does not occur until the flowering or fruiting stage. This might mean that all cannabis seeds and immature plants, regardless of their potential to produce THC in excess of the hemp limit, fit the CSA carve outs for hemp. This could have a significant impact on importing THC-heavy cannabis seeds into the U.S., and federal enforcement efforts relating to cannabis seeds and immature plants.

A recent case in Minnesota highlights the problem. A local hemp farmer faces felony charges over products containing THC levels of greater than 3% — more than 10 times the limit for hemp. According to this news article, the farmer explained that when “he concentrated [the hemp into] the oil, the THC levels can go from 0.3 percent to 2 percent.” It remains unclear whether there is a one-time hemp test for THC that applies sometime after harvest, or if hemp and hemp derivatives must continually fall below 0.3% THC. The news article quotes Thomas Gallager, a criminal defense attorney that is also on the board for the local NORMAL chapter, “federal law exempts THC derived from hemp.” This particular case may turn on the state’s controlled substances act rather than federal law. Federal law will likely remain unsettled until there is clearer guidance from the DEA or other federal authorities.

 

Last week, the U.S. Postal Service (USPS) confirmed in an expanded policy update that hemp and hemp products are mailable under certain circumstances, as set forth below.

In a statement published to the agency’s Postal Bulletin, USPS said that since the passage of the 2018 Farm Bill it has “received numerous inquiries from commercial entities and individuals wishing to use the mail to transport cannabidiol (CBD) oil and various other products derived from the cannabis plant.” As a response, in March, the institution issued internal guidelines on the matter and is now further clarifying what it considers mailable. The requirements under the updated policy are as follow:

Hemp and hemp-based products, including cannabidiol (CBD) with the tetrahydrocannabinol (THC) concentration of such hemp (or its derivatives) not exceeding a 0.3 percent limit are permitted to be mailed only when:

a. The mailer complies with all applicable federal, state, and local laws (such as the Agricultural Act of 2014 and the Agricultural Improvement Act of 2018) pertaining to hemp production, processing, distribution, and sales; and

b. The mailer retains records establishing compliance with such laws, including laboratory test results, licenses, or compliance reports, for no less than 2 years after the date of mailing.

The previous guidance required mailers to provide USPS with a signed self-certification statement, a document showing that the mailer has authorization to market the products pursuant to a state Department of Agriculture license, and a lab report detailing the THC concentration of the products. Under the new guidelines, “a mailer is not required to present the documentation at the time of mailing, but such documentation may be requested either at that time or on a later date if there is doubt about the item’s mailability or the addressee’s ability to legally receive it,” USPS wrote. “This process is consistent with existing regulations governing questions about mailability of restricted matter.”

The agency also said that it expects to further clarify mailability issues surrounding hemp products after the U.S. Department of Agriculture adopts hemp production regulations under the 2018 Farm Bill.

The Washington State Bar Association Cannabis Law Section is hosting a webinar on the state of hemp-derived cannabidiol (CBD) in Washington and across the U.S. The panelists will discuss legal considerations for advising businesses cultivating hemp, processing raw hemp into finished products and distributing hemp-derived CBD. They will also provide insights on the 2014 and 2018 Farm Bills, FDA regulations and policies, and recent changes to Washington law regarding hemp.

FACULTY

  • Joshua Ashby, Lane Powell
  • Daniel Shortt, Harris Bricken
  • Ammon Ford, Gleam Law
  • Anastasia Gilmartin, OLEO, Inc.
  • Sativa Rasmussen, Lane Powell

SCHEDULE

  • 1 p.m. Webinar Login Opens
  • 1:30 p.m. Webinar Begins
  • 2:30 p.m. Adjourn

Register today!

Barry Abbott and Jimmy Zack authored an article titled “Current Banking Issues in the Cannabis Industry” for The Consumer Finance Law Quarterly Report,  Vol. 72, No. 4, at 390 (2018). The article explores the growth of the U.S. legal marijuana market, which is expected to exceed $23 billion by 2022, as well as the impact that federal prohibitions on marijuana have on banking in the industry, leading to significant public safety concerns and extensive security expenses.

… The so-called ‘Sessions Memo’ (rescinding the Cole Memo on January 4, 2018) caused virtually all national financial institutions to refuse to engage with any marijuana-related businesses, even as those institutions were already reluctant to engage with marijuana-related businesses while the Cole Memo was still in effect.

Read the article.

By a 19-9 vote, the Oregon Senate has passed Senate Bill 582, which authorizes the Governor to enter into agreements with other states for the purposes of “cross-jurisdictional coordinate and enforcement” of marijuana-related businesses and “cross-jurisdictional delivery of marijuana items” between Oregon and other states. The bill moves to the House where it has bipartisan support, and the Governor is expected to sign.

So what does this mean for Oregon cannabis businesses? For now, not much. There are at least two additional obstacles before marijuana import/export can start. First, SB 582 becomes operative only on the occurrence of either: 1) the amendment of federal law to allow for the interstate transfer of marijuana, or 2) the U.S. Department of Justice (DOJ) issues an opinion or memorandum “allowing or tolerating” the interstate transfer of marijuana. Second, SB 582 contemplates an “agreement with another state,” which means that another state would have to pass similar enabling legislation, and the two states would then have to negotiate an agreement.

As to the federal issue, there are a few existing paths forward. Elizabeth Warren (D-Mass.) and Cory Gardner (R-Colo.) recently reintroduced the STATES Act, which would carve out state law-compliant cannabis activity from the Controlled Substances Act. Agreements of the kind contemplated by SB 582 could be legal if the STATES Act passes. Alternately, a Cole-like memorandum from the DOJ “allowing or tolerating” interstate commerce isn’t out of the question — U.S. Attorney General William Barr is on record favoring reform of federal cannabis laws.

As to the state issue, Oregon is the first to advance this kind of legislation this far. While others may follow, interstate commerce raises a host of issues affecting intrastate cannabis industries. As we’ve written about here, Oregon faces a significant oversupply of adult use cannabis, and would benefit from the ability to export it. Growers in other states might feel differently, and there could well be lobbying in the other direction as other states’ cannabis industries come online, mature and organize.

Stay tuned here for the latest, and as always, our Cannabis team is standing by.